Core Viewpoint - The surge in Hong Kong IPOs has attracted bank wealth management subsidiaries, which are increasingly participating in the market to enhance their equity investment capabilities and offer new products to investors [2][8]. Group 1: Market Trends - The Hong Kong IPO market has seen significant growth, with 12 new listings as of January 27, raising a total of HKD 34.747 billion, a year-on-year increase of 480.89% [3]. - Major companies such as Wallen Technology and MiniMax have successfully launched IPOs, indicating a strong interest in hard technology sectors [3][4]. Group 2: Bank Participation - Bank wealth management subsidiaries, such as ICBC Wealth Management, have become active participants in Hong Kong IPOs, with ICBC participating in over 80% of the projects it locked in, achieving a 100% success rate with a maximum single investment return of 165.45% [4][5]. - ICBC Wealth Management has focused its investments on hard technology and high-end manufacturing sectors, including semiconductor and AI companies [5]. Group 3: Product Development - Wealth management subsidiaries are embedding Hong Kong IPO capabilities into their product offerings, with ICBC launching "fixed income + Hong Kong IPO" strategy products aimed at private banking clients [6][7]. - The minimum investment thresholds for these products are set at RMB 200,000 and RMB 1 million, respectively, while some banks are working to lower barriers for retail investors [7]. Group 4: Industry Dynamics - The shift of wealth management funds towards Hong Kong IPOs is driven by the need for higher returns in a low-interest-rate environment, as traditional fixed-income assets are no longer sufficient [8]. - Participation in Hong Kong IPOs allows wealth management firms to enhance their equity investment capabilities and potentially achieve excess returns through strategic investments [8]. Group 5: Challenges Ahead - Despite the opportunities, wealth management firms face challenges in project acquisition, research capabilities, and risk management, necessitating the establishment of a robust primary market research system [9]. - Firms must navigate competition for quality cornerstone shares, enhance cross-market research capabilities, and manage risks associated with market volatility and currency fluctuations [9].

Group 1 - The Hong Kong IPO market has been thriving since January 2026, with 12 companies successfully listed and raising nearly 35 billion HKD as of January 27, 2026 [1] - UBS and Deloitte China predict that the total financing scale of Hong Kong IPOs in 2026 is expected to exceed 300 billion HKD, indicating a strong recovery in the market [4] - The competitive landscape of the Hong Kong investment banking sector is transforming, with both Chinese and international investment banks actively participating, making it a key driver for growth in intermediary institutions [1][2] Group 2 - In 2025, the top ten equity underwriting positions were evenly split between Chinese and international institutions, with Chinese firms holding six positions after mergers [2] - As of January 27, 2026, Chinese institutions occupy seven of the top ten positions in equity underwriting, commanding over 70% of the market share [2] - The demand for Chinese companies to go global is strong, and Chinese brokers are becoming dominant players in the Hong Kong IPO market [2] Group 3 - Morgan Stanley has emerged as the leading equity financing underwriter in the Asia-Pacific region for 2025, significantly benefiting from the resurgence of Hong Kong equity financing [3] - UBS's involvement in major IPOs, including CATL and Heng Rui Medicine, highlights its strong position in the Hong Kong market [4] - The anticipated number of new listings in Hong Kong for 2026 is projected to reach between 150 and 200 companies, with a significant number of large-scale projects expected in the first quarter [4] Group 4 - Hu Zhizhe, President of UBS China, emphasizes Hong Kong's role as a "bridgehead" for connecting Chinese enterprises with global capital, facilitating a two-way flow of investment [4] - Hu also notes that UBS is capturing new opportunities by assisting Chinese companies in accessing international capital markets while helping global capital engage with China's growth story [4] - Recent announcements from Chinese securities firms, such as Huatai Securities and GF Securities, indicate a trend of increasing capital investment to support overseas business development [5][6]

来源：21世纪经济报道 继2025年IPO筹资额重回全球榜首后，进入2026年，港股IPO市场持续火爆。 2026年1月以来（截至1月26日），港交所上市新股数量已经达到了12家，总募资金额为347.47亿元，同比增长了480.87%。其中，国产GPU龙 头壁仞科技以及大模型企业智谱AI、MiniMax相继登陆港股市场，进一步强化了港股在前沿科技领域的融资地位。 1月28日、2月3日，港交所还将迎来两家消费企业，分别是量贩零食企业鸣鸣很忙和功能饮料企业东鹏饮料。前者在1月23日已经完成招股，认 购倍数超过1500倍，首发募资金额33.36亿港元；后者1月26日启动招股，预计募资101.41亿港元。 这也就意味着，截至目前，港股IPO市场已经锁定的融资规模达到482.24亿港元。而当前，还有越来越多的企业对港股市场展现出浓厚的兴 趣，形成了庞大的后备上市梯队。 近日，香港交易所行政总裁陈翊庭在瑞士达沃斯世界经济论坛期间接受采访时表示，香港IPO排队企业数量已超过350家，其中包括保密递交 上市申请的公司。 | 名称 | 上市日期 | 募资总额(亿港元) | | 所属Wind行业 | | --- | --- | ...

近日，新时空研究院发布《2025年港股IPO市场年度报告》。《报告》显示，香港新股市场全年募资总额约2850亿港元，重登全球融资榜首。但这份亮眼成 绩单背后，市场结构性分化达到前所未有的程度——募资额TOP20占据全年75%的份额，近三成新股上市首日破发，流动性与认购热度向头部标的极致集 中。 募资集中度：TOP20拿走75%，A+H巨头主导格局 图片来源：新时空《2025年港股IPO市场年度报告》封面 2025年港股IPO市场募资分布呈现显著的头部集中效应。全年超110宗项目合计募资约2850亿港元，其中募资额排名前20的公司合计占全年总额的75%。"募 资王"宁德时代以356.57亿港元遥遥领先，紫金黄金国际（249.84亿港元）与赛力斯（142.83亿港元）紧随其后。 A+H公司构成募资核心力量。在募资TOP20中，A+H公司占据10席，宁德时代、赛力斯、三一重工三家巨头合计募资633.9亿港元，占全年总额的22.2%。这 些已在A股上市的制造业与消费业龙头，赴港主要动因在于搭建国际资本平台与品牌全球化。 相比之下，18A生物科技公司呈现"数量多、规模小"特征。该板块最大募资额未超20亿港元，劲方医药- ...

本周五， 有关"赴港上市门槛收紧"的传闻引发市场广泛讨论。 该传闻不仅覆盖直接赴港上市的内地企业，还涉及寻求港股双重上市的A股公 司，一度被解读为赴港上市通道"降温"的信号。真实情况如何？ 针对传闻中"已有券商收到指导，要求拟赴港上市的双重企业满足300亿元的市值门槛"，财联社记者向部分券商求证，得到答复均为未收到此类指导 或通知。 同时记者获悉，联交所目前也并未接到"提高赴港上市门槛"的相关通知。 某头部券商投行高管告诉记者， 300亿元的市值标准对于赴港上市企业而言门槛过高，远超当前港股市场多数拟上市主体的规模水平， 设置这一 门槛背后必然有可追溯的潜在考量，但当前落地可能性较低。 另一位头部投行人士也向记者给出了相似结论，原因有二。 一是从监管逻辑来看，突然叫停或实质性收紧赴港上市门槛的可能性存在，但当前概率较低。这是因为，香港资本市场的核心优势在于高度 市场化，本质上只要企业股票能获得市场认可、成功配售，且不存在信息披露造假等违规行为，监管层通常不会刻意设限，通过高门槛"一 刀切"或无必要。 二是港股作为中资企业境外融资的核心平台，在内地上市审核以"质量"为导向的严监管态势下，若同步抬高市值门槛，可能 ...

Core Viewpoint - The article highlights the impressive turnaround of Baiwei Storage under the leadership of Chairman Sun Chengsi, projecting significant profit growth driven by the rising demand for storage chips, particularly in the AI sector. The company aims for an IPO in Hong Kong to expand its operations further [5][9][25]. Group 1: Company Performance - Baiwei Storage is expected to achieve a net profit of 850-1,000 million yuan in 2025, representing a year-on-year increase of 400-500% [5][12]. - The company reported a profit of over 1 billion yuan in just six months, showcasing its rapid recovery and growth [6][12]. - The stock price reached a new high of 145.9 yuan per share on January 14, 2025, indicating strong market confidence [25]. Group 2: Market Dynamics - The storage product prices are projected to follow a "U-shaped" curve, declining until Q1 2025 and then recovering, which will boost sales revenue and gross margins [14]. - The demand for storage is being driven by AI applications, particularly in AI inference, edge AI, and emerging AI applications [17]. - Baiwei's products are being integrated into various sectors, including robotics and consumer electronics, with notable clients like Lenovo and Xiaomi [18][19]. Group 3: Leadership and Strategy - Sun Chengsi, who took over the company at the age of 27, has been instrumental in transforming Baiwei's business model from ODM to a more integrated R&D and packaging approach [7][21]. - The company has established partnerships with major semiconductor manufacturers and has focused on enhancing its packaging and testing capabilities [21][29]. - Baiwei is the only independent storage solution provider globally with wafer-level packaging capabilities, which enhances its competitive edge [29]. Group 4: Future Outlook - Baiwei plans to expand its production capacity significantly, with a fundraising target of approximately 1.9 billion yuan aimed at enhancing its manufacturing capabilities [32]. - The company anticipates that revenue from AI glasses will reach about 106 million yuan in 2024, with expectations of over 500% growth in 2025 [31]. - The management is preparing for a dual listing in Hong Kong, which will further support its growth ambitions [25][26].

2026年以来，来自欧美、中东的国际长线资金密集参与港股IPO。资讯数据显示，截至1月22日，年初 至今已有12家新股上市，累计吸引了137家基石投资者，其中不乏优质的国际长线资金。 1月22日，上海龙旗科技（603341）股份有限公司在港上市，吸引了QualcommVenturesLLC（高通创 投）等基石投资者；1月9日，稀宇科技（MiniMax）上市，其IPO阶段吸引了未来资产证券有限公司、 阿布达比投资局等14家基石投资者，总计投资约为3.5亿美元。1月8日，深圳市精锋医疗科技股份有限 公司在港上市，吸引了阿布扎比投资局等14家基石投资者。1月2日，上海壁仞科技股份有限公司上市， 其IPO阶段吸引了瑞银环球资产管理（新加坡）有限公司等23家基石投资者。 高盛亚洲（除日本外）股票资本市场主管王亚军对《证券日报》表示："未来国际长线资金还会更多。 相较于2021年前后的高点，目前国际长线资金回流比例约在五到六成，未来有望达到七成左右。香港市 场的根本属性是国际金融市场，其健康与活力依赖于吸引并留住全球资本，而这必须通过优质的上市资 产和高效的市场机制来实现。" 国际长线资金涌入 关注企业发展潜力 从资金动 ...

1月19日，国内综合乳制品企业君乐宝乳业集团股份有限公司（以下简称"君乐宝"）正式向香港联交所递交主板上市申请。 | 編纂]的[編纂]數目 | | : [編纂]股H股(視乎[編纂]行使與否而定) | | --- | --- | --- | | [編纂]數目 | .. | [编纂]股H股(可予重新分配) | | [編纂]數目 | : | [編纂]股H股(可予重新分配及視乎[編 | | 纂 行使與否而定) | | | | 最高[編纂] | ： | 每股H股[編纂]港元,另加1.0%經 | | | | 紀佣金 · 0.0027%證監會交易徵 | | | | 費·0.00015%會財局交易徵費及 | | | | 0.00565%聯交所[編纂]費(須於[編纂] | | | | 時以港元繳足,多繳款項可予退還) | | 咱偵 | : | 每股H股人民幣1.00元 | | [編纂] : [編纂] | | | 据君乐宝招股书披露的合规风险，其中涉及物业、劳动用工、资金结算等多个关键环节，部分问题已触及监管红线，可能对上市进程 及后续运营产生实质性影响。 在物业合规方面，公司存在自有物业与租赁物业双重瑕疵。 部分自有物业未取得 ...

Core Viewpoint - Dongning Biotechnology has submitted its IPO application to the Hong Kong Stock Exchange for the third time, following two previous failed attempts in September 2022 and March 2023, with Morgan Stanley and Huatai International as joint sponsors [1]. Group 1: Company Overview - Dongning Biotechnology, established in 2005, specializes in providing comprehensive solutions for the development and commercialization of biopharmaceutical products, being the first domestic provider of serum-free culture media [1]. - The company ranks sixth among all cell culture media suppliers in China, third among domestic suppliers, and fourth among single-use product suppliers, with a market share of 14.3% [1][3]. Group 2: Financial Performance - In the reporting period, the company achieved revenues of RMB 814.08 million, RMB 842.88 million, and RMB 658.93 million, while incurring annual losses of RMB -314.66 million, RMB -27.5 million, and RMB -8.26 million [2][4]. - Despite revenue growth, the company recorded losses in 2023 and 2024, with a net profit margin of only 2.2% in the first three quarters of 2025 [2]. Group 3: Business Segments - The core business consists of two main segments: bioprocess solutions and laboratory products and services, with bioprocess solutions being the primary revenue driver [1][4]. - The revenue contribution from bioprocess solutions was 77.0%, 75.7%, and 77.1% for 2023, 2024, and the first three quarters of 2025, respectively, indicating its dominance in the company's revenue structure [4]. Group 4: IPO Fund Utilization - The funds raised from the IPO will be primarily used for expanding global market reach, strategic acquisitions and equity investments, enhancing R&D capabilities, upgrading existing production capacity, and supplementing working capital [5]. Group 5: Challenges and Risks - The company faces operational challenges, having recorded losses in 2023 and 2024 due to high expenses and changes in the fair value of financial assets [5]. - WuXi Biologics, a major customer, supplier, and shareholder, has created multiple related-party relationships, and the company's goodwill value reached RMB 843 million by the end of the third quarter of 2025, which may impact future operations and valuations [5].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional compliance information from Chengyi Biotechnology regarding its overseas listing application, focusing on three main areas: equity structure, capital situation, and domestic operating entities [1][2][3] Group 1: Compliance Requirements - The CSRC requires Chengyi Biotechnology to clarify the compliance of its equity structure and reverse mergers, including whether shareholders holding over 5% have completed foreign exchange registration and if domestic institutional shareholders have followed necessary regulatory procedures [2] - The company must explain the pricing basis and tax payments related to acquisitions of domestic entities, ensuring compliance with regulations on foreign investment in domestic enterprises [2] - The CSRC also demands a conclusion on whether the equity structure and reverse merger processes adhered to existing foreign exchange management, foreign investment, and tax regulations [2] Group 2: Capital Situation - The CSRC has asked for clarification on the shareholding proportions of key stakeholders and whether they should be consolidated, as well as the specific arrangements regarding special shareholder rights and their impact on control [3] - The company is required to disclose whether there have been any shareholding proxies in its historical evolution and if the pricing for new shareholders in the last 12 months was fair and reasonable [3] - The CSRC seeks a conclusive opinion on whether the equity incentives involving domestic individuals complied with foreign exchange registration requirements [3] Group 3: Domestic Operating Entities - Chengyi Biotechnology must provide details on its wholly-owned subsidiary, Shanghai Chengyi, which holds a patent for an extracellular gene expression intervention method, and whether its business aligns with the negative list of foreign investment access [3] - The company is required to disclose any significant litigation, arbitration, or administrative penalties affecting its domestic operations [3] - A conclusive opinion on the legality and compliance of the establishment and historical equity changes of domestic operating entities is also required [3] Group 4: Financial Performance - Chengyi Biotechnology reported revenues of $36.06 million, $221 million, and $557,000 for the years 2023, 2024, and the first half of 2025, respectively, with net profits of -$52.23 million, $139 million, and -$20.11 million during the same periods [4] - The company has only one customer, AstraZeneca, which is also a shareholder, generating revenues of $36 million, $221 million, and $55,680 from this customer in the respective years [4] Group 5: Competitive Landscape - Chengyi Biotechnology believes its pipeline strength and proprietary TRANDD platform provide a significant competitive advantage, but it faces potential competition from multinational pharmaceutical companies and other biotech firms [5] - The company heavily relies on the success of its candidate drugs, and any failure to complete development, obtain regulatory approval, or commercialize these drugs could significantly harm its business and financial outlook [5]